Q2 EPS Estimates for Gossamer Bio Raised by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – Analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Gossamer Bio in a research report issued on Thursday, June 25th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.04) per share for the quarter, up from their previous forecast of ($0.09). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.23) EPS, Q1 2027 earnings at ($0.04) EPS, Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.11) EPS, FY2028 earnings at ($0.08) EPS and FY2029 earnings at ($0.04) EPS.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $16.95 million during the quarter, compared to the consensus estimate of $4.67 million.

Several other analysts have also recently weighed in on the stock. Oppenheimer reduced their target price on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. Weiss Ratings downgraded shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Gossamer Bio in a report on Monday, March 23rd. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $4.50.

Gossamer Bio Stock Performance

Shares of Gossamer Bio stock opened at $0.16 on Monday. The business has a 50-day simple moving average of $0.26 and a 200-day simple moving average of $1.26. Gossamer Bio has a one year low of $0.14 and a one year high of $3.87. The company has a market cap of $37.55 million, a PE ratio of -0.20 and a beta of 2.00.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. Corient Private Wealth LLC increased its holdings in shares of Gossamer Bio by 19,123.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after acquiring an additional 3,825,879 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Gossamer Bio during the 4th quarter worth $35,000. Merit Financial Group LLC boosted its stake in Gossamer Bio by 15.2% during the 4th quarter. Merit Financial Group LLC now owns 155,178 shares of the company’s stock worth $481,000 after purchasing an additional 20,490 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Gossamer Bio during the 4th quarter worth $148,000. Finally, Tudor Investment Corp ET AL grew its position in Gossamer Bio by 7.8% during the 3rd quarter. Tudor Investment Corp ET AL now owns 50,103 shares of the company’s stock worth $132,000 after purchasing an additional 3,639 shares during the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Key Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across several periods, including FY2026, FY2027, FY2028 and FY2029, signaling improving expectations for Gossamer Bio’s future profitability. Gossamer Bio analyst update
• Positive Sentiment: The firm maintained a Buy rating and a $2.00 price target, which remains well above the stock’s recent trading level and suggests meaningful upside if execution improves. Gossamer Bio analyst update
• Neutral Sentiment: Despite the raised estimates, HC Wainwright still expects Gossamer Bio to remain unprofitable in the forecast period, with losses projected for 2026 through 2029. Gossamer Bio analyst update
• Neutral Sentiment: The consensus view still calls for a full-year loss, so the stock’s move likely reflects a mix of optimism about improving fundamentals and caution over ongoing dilution or execution risk. Gossamer Bio analyst update

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.